HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.

AbstractAIM:
To evaluate the efficacy of infliximab treatment in patients with refractory uveoretinitis associated with Behçet's disease.
METHODS:
Clinical records of 14 patients were retrospectively reviewed. Patients received infliximab infusions (5 mg/kg) at weeks 0, 2 and 6, and every 8 weeks thereafter. The main outcome measures were frequency of clinically observable ocular inflammatory attacks, background retinal and disc vascular leakage as assessed by fluorescein angiography during periods of clinical quiescence, visual acuity and adverse effects.
RESULTS:
The median follow-up after initiating infliximab therapy was 19 months (range 12-29 months). At 12 months, eight of 14 patients (57%) had experienced no inflammatory attacks, and the frequency of attacks was significantly reduced when compared with the 6-month period just prior to infliximab use. Background retinal and disc vascular leakage assessed at 12 months improved in 11 of 14 patients (79%). Visual acuity improved or remained unchanged at 12 months in 26 of 28 eyes (93%). Infliximab therapy was terminated in two patients owing to infusion reactions. However, no serious adverse effects were observed.
CONCLUSION:
Infliximab over the first year of treatment appeared effective in reducing ocular inflammatory attacks, as well as background retinal and disc vascular leakage, in patients with refractory uveoretinitis associated with Behçet's disease.
AuthorsHiroshi Keino, Annabelle A Okada, Takayo Watanabe, Wakako Taki
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 95 Issue 9 Pg. 1245-50 (Sep 2011) ISSN: 1468-2079 [Electronic] England
PMID21183514 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Infliximab
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal (administration & dosage)
  • Behcet Syndrome (complications, drug therapy, pathology)
  • Dose-Response Relationship, Drug
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Immunosuppressive Agents (administration & dosage)
  • Infliximab
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Optic Disk (drug effects, pathology)
  • Retina (drug effects, pathology)
  • Retinitis (etiology, pathology, prevention & control)
  • Retrospective Studies
  • Treatment Outcome
  • Visual Acuity
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: